Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mereo BioPharma Group (MREO) Current Assets: 2020-2024

Historic Current Assets for Mereo BioPharma Group (MREO) over the last 5 years, with Dec 2024 value amounting to $74.8 million.

  • Mereo BioPharma Group's Current Assets fell 39.57% to $52.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $52.4 million, marking a year-over-year decrease of 39.57%. This contributed to the annual value of $74.8 million for FY2024, which is 17.26% up from last year.
  • Per Mereo BioPharma Group's latest filing, its Current Assets stood at $74.8 million for FY2024, which was up 17.26% from $63.8 million recorded in FY2023.
  • Over the past 5 years, Mereo BioPharma Group's Current Assets peaked at $133.9 million during FY2021, and registered a low of $38.2 million during FY2020.
  • Moreover, its 3-year median value for Current Assets was $74.8 million (2024), whereas its average is $71.2 million.
  • As far as peak fluctuations go, Mereo BioPharma Group's Current Assets surged by 250.75% in 2021, and later plummeted by 43.84% in 2022.
  • Yearly analysis of 5 years shows Mereo BioPharma Group's Current Assets stood at $38.2 million in 2020, then soared by 250.75% to $133.9 million in 2021, then slumped by 43.84% to $75.2 million in 2022, then decreased by 15.21% to $63.8 million in 2023, then climbed by 17.26% to $74.8 million in 2024.